Study of the Native Outflow Tract Transcatheter Pulmonary Valve (TPV)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-10-31

Study Completion Date

2020-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this early feasibility study is to determine how a new transcatheter pulmonary valve will move and perform once implanted in the right ventricular outflow tract.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Feasibility Study to Evaluate the Safety and Short-term Effectiveness of Transcatheter Pulmonary Valve (TPV)

NCT02555319

Congenital Heart Defects Cardiovascular Abnormalities Pulmonary Valve Insufficiency +1 more

COMPLETED NA

Melody Transcatheter Pulmonary Valve Study: Post Approval Study of the Investigational Device Exemption Cohort

NCT00740870

Congenital Heart Defects Dysfunctional Right Ventricular Outflow Tract Conduits

COMPLETED NA

Melody® Transcatheter Pulmonary Valve Post-Approval Study

NCT01186692

Dysfunctional Right Ventricular Outflow Tract (RVOT) Conduit

COMPLETED NA

TTVR Early Feasibility Study

NCT04433065

Tricuspid Regurgitation

RECRUITING NA

Pacemaker Implantation Following Transcatheter Tricuspid Valve Replacement

NCT06814574

AV Block Complete Tricuspid Regurgitation (TR)

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Medtronic, Inc. is in the process of developing a novel transcatheter device option for patients with congenital heart disease, without right ventricle-to-pulmonary artery conduits, called the Native Outflow Tract Transcatheter Pulmonary Valve. Given limitations in the animal model to confirm device boundary conditions, this feasibility study is proposed to characterize that information as well as evaluate safety, procedural feasibility and performance data to be used for future development of the device.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Congenital Heart Disease Tetralogy of Fallot

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DEVICE_FEASIBILITY

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Native Outflow Tract TPV

Implantation of the Native Outflow Tract TPV

Group Type EXPERIMENTAL

Native Outflow Tract TPV

Intervention Type DEVICE

Transcatheter placement of a pulmonary valve

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Native Outflow Tract TPV

Transcatheter placement of a pulmonary valve

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Native TPV

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subject has pulmonary regurgitation as per one or more of the following criteria: Severe pulmonary regurgitation as measured by Doppler echocardiography, or Pulmonary regurgitant fraction ≥ 30% as measured by cardiac magnetic resonance imaging
* Clinical indication for surgical placement of a RVOT conduit or bioprosthetic pulmonary valve per one or more of the following criteria: Subject is symptomatic secondary to pulmonary insufficiency (e.g. exercise intolerance, fluid overload) as classified by the Investigator, or Right ventricular end diastolic volume (RVEDV) ≥ 150 ml/m2
* Subject is willing to consent to participate in the study and will commit to completion of all follow-up requirements

Exclusion Criteria

* Anatomy unable to accommodate a 25 Fr delivery system
* Obstruction of the central veins
* Clinical or biological signs of infection including active endocarditis
* Indicated for intervention of stenosis of the branch pulmonary arteries at time of implant
* Positive pregnancy test at baseline (prior to CT angiography and again prior to implant procedure) in female subjects of child bearing potential
* Patients with right ventricular outflow tract obstruction (RVOTO) lesions surgically treated with a right ventricle-to-pulmonary artery conduit implant
* A major or progressive non-cardiac disease (e.g. liver failure, renal failure, cancer) that results in a life expectancy of less than one year
* Planned implantation of the Native Outflow Tract TPV in the left heart
* RVOT anatomy or morphology that is unfavorable for anchoring
* Known allergy to aspirin, heparin, or nickel
* Echocardiographic evidence of intracardiac mass, thrombus, or vegetation
* Pre-existing prosthetic heart valve or prosthetic ring in any position
* Patient is currently enrolled in another investigational device or drug trial that may influence the outcome of this trial.

Eligible Sex

ALL

Accepts Healthy Volunteers

No